back to US directory
us clinical guidance

First-episode psychosis and schizophrenia care

VA/DoD-aligned early recognition, medical and substance differential, coordinated specialty care and antipsychotic safety monitoring.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected first-episode psychosis or established schizophrenia. The 2023 VA/DoD guideline spans primary-care recognition, specialty assessment and pharmacotherapy. Delirium, intoxication or withdrawal, postpartum psychosis, pediatric-onset illness, severe agitation and neurologic emergencies need condition-specific urgent pathways.
sources for this section:VA/DoD psychosis 2023

The Bottom Line

  • Recognize hallucinations, delusions, disorganized thought or behavior, negative symptoms and functional decline, while distinguishing psychosis from culturally sanctioned beliefs, trauma phenomena and communication difference.
  • Assess medical, neurologic, medication and substance causes and establish the timeline before assigning schizophrenia; first-episode psychosis is a presentation, not a final etiologic diagnosis.
  • Link early to coordinated specialty care that integrates appropriately selected antipsychotic treatment, psychotherapy, family education, supported education or employment and substance-use care.
  • Use shared decision-making for antipsychotic selection and route, considering prior response, adverse-effect profile, adherence barriers, physical health, patient preference and current FDA labeling.
sources for this section:VA/DoD psychosis 2023

Practical clinical workflow

1
Interview the patient directly and obtain collateral information with consent about onset, behavior, sleep, mood, cognition, trauma, function, substances, prescribed or nonprescribed medicines and safety.
2
Perform mental-state, neurologic and physical examination and targeted testing for plausible causes; avoid indiscriminate panels while acting urgently on delirium, fever, focal signs, seizures or toxic exposure.
3
Agree on treatment goals, initiate or optimize guideline-supported care and document baseline weight, cardiometabolic status, movement symptoms, sexual or endocrine concerns and other product-specific risks.
4
Monitor symptoms, function, adherence, substance use, metabolic health, extrapyramidal effects, tardive dyskinesia and prolactin-related effects and address housing, benefits and family or caregiver needs.
sources for this section:VA/DoD psychosis 2023

Safety boundaries and escalation

  • Command hallucinations, suicidal or violent intent, severe agitation, catatonia, inability to meet basic needs or rapidly worsening behavior requires immediate risk assessment and a safe level of care.
  • Abrupt onset with fluctuating attention, fever, autonomic instability, seizure, focal deficit, rigidity or toxic exposure suggests delirium or another medical emergency rather than uncomplicated schizophrenia.
  • High fever, severe rigidity, altered consciousness or autonomic instability during antipsychotic treatment requires emergency assessment for neuroleptic malignant syndrome and other acute causes.
  • Do not discontinue antipsychotic therapy suddenly solely because the patient is improved or an adverse effect appears; address toxicity promptly and coordinate a monitored switch or taper when appropriate.
sources for this section:VA/DoD psychosis 2023VA/DoD suicide risk 2024

Localization

US early-psychosis programs, Medicaid eligibility, civil commitment standards, assisted-outpatient treatment and long-acting-injection coverage vary substantially. VA/DoD recommendations inform care but local law and FDA labeling govern implementation.
sources for this section:VA/DoD psychosis 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and SchizophreniaVersion 2.0 (2023); official guideline page updated 2025-06-11 路 updated 2025-06-11 路 accessed 2026-08-20
    view source
  2. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide2024 guideline; official guideline page checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.